Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Oropharyngeal Squamous Cell Carcinoma: early-phase trial registry
11 of 15 indexed Oropharyngeal Squamous Cell Carcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,140 of 28,707 conditions by registered trial count.
15 US clinical trials · 11 currently recruiting · #1,140 of 28,707 conditions by registered trial count
Oropharyngeal Squamous Cell Carcinoma: 15 US clinical trials tracked, 11 recruiting.
Oropharyngeal Squamous Cell Carcinoma is the subject of 15 registered US clinical trials on ClinicalTrials.gov, 11 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 2 of these trials.
Enrollment posture brief
Registry condition oropharyngeal-squamous-cell-carcinoma
OPEN 11 | RECR 73% | LATE 0 | EARLY 9 | RANK #1140 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Peritoneal Carcinomatosis (73% recruiting · 15 trials)
Oropharyngeal Squamous Cell Carcinoma lists 11 open slots (73% of 15 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Oropharyngeal Squamous Cell Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Oropharyngeal Squamous Cell Carcinoma is recruiting above its size-band peers.
11 of 15 indexed trials (73.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Oropharyngeal Squamous Cell Carcinoma trials is spread across many organizations.
National Cancer Institute (NCI) accounts for 2 of 15 trials (13.3%). 14 distinct sponsors appear on at least one study for this condition label.
-
Typical Oropharyngeal Squamous Cell Carcinoma enrolment sits around 112 participants.
Median target enrolment is 112 among the 15 trials that report a genuine target (sentinel values excluded). 7 of those (46.7%) plan for fewer than 100 participants.
-
Oropharyngeal Squamous Cell Carcinoma splits between interventional and observational designs.
10 interventional and 5 observational studies make up this index (66.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
15 total, page 1 of 1
Validity of Viome's Oral/throat Cancer Test
Viome
NCT06174428
Oropharynx (OPX) Biomarker Trial
Mayo Clinic
NCT06356272
Risk Adapted De-Intensification of Radio-Chemotherapy for Oropharyngeal Squamous Cell Carcinoma
University of Florida
NCT05268614
Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCC
UNC Lineberger Comprehensive Cancer Center
NCT04564989
People Living With HIV, Oral and Oropharyngeal Cancer, and Health Equity
University of California, San Francisco
NCT06055868
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
NRG Oncology
NCT06532279
Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer
Ohio State University Comprehensive Cancer Center
NCT06323460
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
National Cancer Institute (NCI)
NCT06980038
Shortened Course of Radiation Therapy After Trans-oral Robotic Surgery in Patients With HPV-Mediated Oropharyngeal Squamous Cell Carcinoma.
University of Utah
NCT07044635
Three Schedules of CUE-101 Administered Before Surgery or Definitive Chemoradiation Therapy in HLA-A*0201 Positive Patients With Locally Advanced, HPV16-Positive Oropharyngeal Squamous-Cell Carcinoma
Washington University School of Medicine
NCT04852328
Comparing an Investigational Scan (F-18 NaF PET/CT) to Standard of Care Imaging (F-18 FDG PET/CT) for Evaluating Vascular Complications in Patients Receiving Radiation Therapy for Head and Neck Cancer
Emory University
NCT06914999
De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer
National Cancer Institute (NCI)
NCT03952585
Post-treatment Surveillance in HPV+ Oropharyngeal SCC
Dana-Farber Cancer Institute
NCT04965792
Selective Avoidance of Nodal VolumEs at Minimal Risk (GCC 20110)
University of Maryland, Baltimore
NCT04609280
The Sinai Robotic Surgery Trial in HPV Positive Oropharyngeal Squamous Cell Carcinoma (SCCA) (SIRS TRIAL)
Icahn School of Medicine at Mount Sinai
NCT02072148
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 8 |
Top Sponsors
Named interventions
Most-linked intervention names on Oropharyngeal Squamous Cell Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Oropharyngeal Squamous Cell Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Oropharyngeal Squamous Cell Carcinoma page
15 registered trials, 11 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 11 Oropharyngeal Squamous Cell Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Oropharyngeal Squamous Cell Carcinoma trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Oropharyngeal Squamous Cell Carcinoma condition card totals 15 registered trials; most-linked intervention Computed Tomography; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.